Table 3 Effects of non-alcoholic fatty liver disease and prognostic factors on overall survival after Immune checkpoint inhibitor therapy in univariate and multivariate Cox regression models
Parameter | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
Gender | ||||
Male | Reference | |||
Female | 0.846 (0.485—1.473) | 0.554 | ||
Age | ||||
< 65 | Reference | Reference | ||
≥ 65 | 1.710 (1.204—2.429) | 0.003 | 1.537 (1.061—2.227) | 0.023 |
Body mass index (kg/m2)* | ||||
< Median | Reference | |||
≥ Median | 1.046 (0.671—1.631) | 0.842 | ||
ECOG performance status | ||||
0 | Reference | Reference | ||
≥ 1 | 1.874 (1.325—2.650) | < 0.001 | 1.654 (1.161—2.355) | 0.005 |
Diabetes | ||||
No | Reference | |||
Yes | 1.522 (0.901—2.570) | 0.116 | ||
Hypertension | ||||
No | Reference | Reference | ||
Yes | 1.695 (1.193—2.408) | 0.003 | 1.471 (1.018—2.127) | 0.040 |
Smoking | ||||
No | Reference | |||
Yes | 0.972 (0.686—1.376) | 0.871 | ||
Hyperlipidemia | ||||
No | Reference | |||
Yes | 1.053 (0.726—1.527) | 0.785 | ||
Total bilirubin | 1.022 (0.990—1.056) | 0.179 | ||
Albumin/Globulin ratio | 0.485 (0.271—0.867) | 0.015 | 0.636 (0.334—1.210) | 0.168 |
lactic dehydrogenase | 1.003 (1.002—1.004) | < 0.001 | 1.002 (1.001—1.003) | < 0.001 |
Hemoglobin (g/L) | 0.987 (0.976—0.997) | 0.014 | 0.993 (0.981—1.004) | 0.199 |
Blood urea nitrogen | 0.968 (0.875—1.071) | 0.531 | ||
Serum creatinine | 1.005 (0.994—1.017) | 0.382 | ||
Pathological types | ||||
adenocarcinoma | Reference | |||
squamous carcinoma | 0.847 (0.594—1.207) | |||
other | 0.542 (0.218—1.345) | |||
Types of ICIs | ||||
PD-1 antibody | Reference | |||
PD-L1 antibody | 0.917 (0.466—1.807) | 0.803 | ||
Stages | ||||
Stage III | Reference | Reference | ||
Stage IV | 1.921 (1.223—3.017) | 0.005 | 1.800 (1.132—2.862) | 0.013 |
Groups | ||||
Non-NAFLD | Reference | |||
NAFLD | 1.039 (0.694—1.558) | 0.851 | ||